pharma · Alzheimer Disease · Amyotrophic Lateral Sclerosis · AMLX
Amylyx Pharmaceuticals EMEA
Amylyx Pharmaceuticals EMEA B.V.
Amylyx Pharmaceuticals EMEA patent portfolio — 9 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Employees
- 167
- Programs
- 7
- Drugs
- 2
- Patents
- 9
Amylyx Pharmaceuticals EMEA patents
9 pharmaceutical patents indexed for Amylyx Pharmaceuticals EMEA. 0 expire within 24 months.
Amylyx Pharmaceuticals EMEA has 9 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 12246027
Compositions of bile acids and phenylbutyrate compounds
granted -
US 12186330
Compositions for improving cell viability and methods of use thereof
granted -
US 12138272
Methods and compositions for treating amyotrophic lateral sclerosis
granted -
US 11583542
Compositions of bile acids and phenylbutyrate compounds
granted -
US 11559533
Compositions of bile acids and phenylbutyrate compounds
granted -
US 11071742
Compositions for improving cell viability and methods of use thereof
granted -
US 10857162
Compositions for improving cell viability and methods of use thereof
granted -
US 10251896
Compositions for improving cell viability and methods of use thereof
granted -
US 9872865
Compositions for improving cell viability and methods of use thereof
granted
Frequently asked questions
How many patents does Amylyx Pharmaceuticals EMEA have?
9 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Amylyx Pharmaceuticals EMEA patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.